Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs DoorDash Inc (DASH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs DoorDash Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.04 (market cap $39.89B), while DoorDash Inc trades at $193.15 (market cap $83.58B). The key difference: DoorDash Inc is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap, and DoorDash Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DASH | |
|---|---|---|
Market Cap | $39.89B | $83.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $281.74 |
52-Week Low | $278.09 | $146.60 |
Enterprise Value | $38.15B | $81.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DoorDash (DASH) trades at $191.82, down 0.28% on the day, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, reaching $13.72 billion in 2025, and has turned profitable with a net income margin of 6.29%. Recent news highlights expansion into grocery delivery and AI integration, while technical indicators suggest key resistance near $200.
The outlook remains positive due to market dominance and international expansion, but risks include intense competition and valuation concerns with a P/E of 90.91. Analysts project a consensus price target of $231.50, implying significant upside, though upcoming Q2 2026 earnings on August 5 will be critical for momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
